Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
EIP Pharma
Biotech
CervoMed's ex-Vertex drug fails to reduce dementia symptoms
CervoMed’s ex-Vertex drug has failed to reduce the severity of patients’ dementia in a phase 2 trial, halting plans for a late-stage study.
James Waldron
Dec 10, 2024 8:20am
EIP fuses with Diffusion to get ex-Vertex drug to dementia data
Mar 30, 2023 8:12am
EIP Pharma tees up phase 3 for ex-Vertex dementia drug
Nov 9, 2020 9:35am
EIP bags cash to trial ex-Vertex drug in dementia, Huntington's
Apr 15, 2019 9:10am
EIP Pharma nabs $20.5M to push Alzheimer's drug through phase 2
May 16, 2018 7:00am
